登录 | 注册    关注公众号  
微信公众号
搜索
 >  Cell>PD-L1 >CHEK-ATP002

HEK293/Human PD-L1, GFP Tag Stable Cell Line

For research use only.

描述(Description)

Binding assay by FACS and cell based ELISA.

应用说明(Application)

Human PD-L1, GFP Tag-HEK293 cells stably expressing exogenous human PD-L1 (Programmed cell death 1 ligand 1, CD274, B7-H1, PDCD1L1, PDCD1LG1, AA sequence : Leu 19 - Leu 238, Protein Acc.# : Q9NZQ7-1). At the same time, GFP protein as a marker was expressed in HEK239/hPD-L1 cells for screening positive cells by FACS.

生长特性(Growth Properties)

Adherent

筛选标记(Selection Marker)

G418 (0.5mg/mL)

培养基(Culture Medium)

DMEM medium +10% FBS

冻存液(Freeze Medium)

20% FBS+10% DMSO+70% DMEM medium

装量(Quantity)

1 vial contains ~ 5x10^6 cells in 1 ml of 10% DMSO in (DMEM+22%FBS).

存储(Storage)

Frozen in liquid nitrogen.

支原体检测(Mycoplasma Testing)

Negative

无菌检测(Sterility Testing)

Negative

使用说明(Instructions for Use)

See data sheet for detailed culturing and assay protocol.

 

Receptor Assay

PD-L1 FACS

Flow Cytometry assay shows that PE-Labeled Human PD-1, Fc Tag, His Tag (recommended for neutralizing assay) (Cat. No. PD1-HP2F2) can bind to 293T cells overexpressing human PD-L1. 1 μl stock solution per million cells (Routinely tested).

Protocol

PD-L1 FACS

FACS analysis shows that the binding of PE-Labeled Human PD-1, Fc Tag, His Tag (recommended for neutralizing assay) (Cat. No. PD1-HP2F2) to 293T overexpressing PD-L1 was inhibited by increasing concentration of neutralizing anti- human PD-L1 antibody. The IC50 is 0.29 μg/ml (Routinely tested).

Protocol

如有相关细胞池需求请联系我们

 

Permits & Restrictions

This cell line is provided for research use only. It is not intended for any animal or human therapeutic use, any human or animal consumption, or any diagnostic use. You are not allowed to share, distribute, sell, modify, sublicense, or otherwise make this cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. AcroBiosystems does not warrant the suitability of this cell line for any particular use, and does not accept any liability in connection with the handling or use of this cell line.

 

前沿进展

 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
PD-L1靶点信息
英文全称:Programmed death-ligand 1
中文全称:程序性死亡配体1
种类:Homo sapiens
上市药物数量:7详情
临床药物数量:156详情
最高研发阶段:临床二期
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定